Axtria Valuation, Funding & Investors

Axtria is valued at $900M as of May 2021.

Last Axtria valuation

$900M

Undisclosed stage · May 2021

Last Axtria funding round

$150M

Undisclosed stage · May 2021

Cumulative funding Axtria raised

$202M

across 5 funding rounds

Key investors in Axtria

  • Bain Capital
  • Helion Venture Partners
  • Kedaara Capital
  • Sparta Group
  • Richard Braddock
  • Amarpreet Sawhney

Axtria Overview

About Axtria

Axtria is a Berkeley Heights-headquartered provider of cloud software for life sciences commercialization. The company offers platforms like SalesCAST for territory alignment and Patient Access for adherence management, serving pharmaceutical firms such as Pfizer and Novartis. Axtria processes commercial data to support field force optimization and patient outcomes across North America and Europe. Founded in 2010, it maintains development centers in India for analytics innovation.


Founded

2010

HQ

United StatesBerkeley Heights, NJ

Website

axtria.com

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$900M (May 2021)

Axtria Valuation

Axtria is currently valued at $900M, based on its undisclosed-stage round in May 2021.

The $150M round was led by Bain Capital.

Axtria valuation by funding round

Axtria valuation by funding round
DateStageValuation
May 2021Undisclosed stage$900M

Axtria Funding History

Axtria has raised a total of $202M across 5 funding rounds, plus 1 secondary share sale.

Axtria's first fundraising round was a $5M Series A in January 2014. The most recent completed round was a $150M undisclosed-stage round in May 2021.

Axtria funding rounds

Axtria funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2025SecondaryKedaara Capital (lead)$240M-Axtria is a leading Agentic AI-first data analytics and cloud software company serving the global life sciences industry. On September 23, 2025, Kedaara Capital, an India-based private equity firm, completed a $240 million transaction structured as a combination of secondary investment and company-sponsored employee share buyback, providing liquidity to current and former Axtria employees and early investors. This marks one of the largest employee-centric liquidity events in the industry and positions Kedaara as a growth partner to support Axtria's expansion of its AI-driven offerings. Previously, Axtria received a $150 million growth investment from Bain Capital Tech Opportunities in May 2021 to accelerate its SaaS platforms, AI/ML capabilities, organic growth, and M&A. Axtria's total funding prior to the Kedaara deal reached $199 million, with a reported valuation of $1 billion as of April 2021. Kedaara manages over $5.5 billion in assets across sectors including technology, pharma/healthcare, and business services, employing an operating partner model with former CEOs.
May 2021Undisclosed stageBain Capital (lead)$150M$900MAxtria is a global cloud software and data analytics provider founded in 2010 that helps life sciences companies bring therapeutics to market faster through AI and machine learning-driven advanced analytics. The company provides mission-critical SaaS platforms focused on data management and therapeutic commercialization, serving more than 100 life sciences companies including 12 of the top 20 global pharmaceutical leaders and eight of the world's top 10 pharmaceutical companies. On May 13, 2021, Axtria secured a $150 million growth investment from Bain Capital Tech Opportunities, its first institutional funding round. Following this investment, the company was valued at approximately $1 billion based on reports from unnamed sources with knowledge of the matter, as confirmed by Bloomberg. CEO Jassi Chadha stated that the funding would enable Axtria to double down on its commitment to making the industry future-ready through record investments in SaaS products and embedding AI and machine learning-driven advanced analytics across all service levels. At the time of the funding announcement, Axtria was already operating at a profit and had built a substantial global presence with 75% of its workforce located in India. The company operated in 75 countries and served a diverse client base across the life sciences and healthcare sectors. CEO Chadha indicated that Axtria could be ready to pursue a public offering within three to five years following the investment. Bain Capital Managing Director Darren Abrahamson highlighted that Axtria addresses a unique pain point in the life sciences industry by helping pharmaceutical companies leverage their vast data resources through intelligent decision-making tools. The partnership aimed to support organic growth initiatives, M&A opportunities, and new product development while facilitating Axtria's international expansion and greater access to major pharmaceutical firms.
Dec 2018Series A-$12M--
Jul 2015Series CHelion Venture Partners (lead); Sparta Group; Amarpreet Sawhney; Farhad Khosravi; Richard Braddock$30M-Axtria Inc., a US-based business analytics provider with a significant presence in India through its Gurgaon office, raised $30 million in its Series C funding round led by Helion Venture Partners, which invested about $15 million. Existing investors including Amar Sawhney, Rick Braddock, Fred Khosravi, and Gururaj 'Desh' Deshpande also participated. The round came in two tranches, with the first early in 2015 and the second larger chunk closed in May 2015. Funds were allocated to increase headcount, build a sales force, augment marketing, and develop new products. Sanjeev Aggarwal from Helion joined the board. Axtria specializes in proprietary cloud-based analytical applications supporting over 60 clients in the US across pharmaceuticals, financial services, retail, and high tech, with more than 10,000 users. It operates an onsite/offshore model from India and plans to expand into Europe. The company positions itself at the intersection of industry domain expertise, technology, analytics, and services in the growing analytics services market, estimated at over $20 billion. CEO Jassi Chadha highlighted ambitions to build a $1 billion revenue business while scaling profitably. Previous funding included a $2.5 million Series A led by Sequoia Capital in 2010 and around $9-10 million across two subsequent tranches. Helion views Axtria as part of India's shift toward analytically powered data services leveraging statistical expertise.
Jan 2015Series B-$6M-Axtria, founded in 2010 by Jaswinder Chadha, provides big data analytics services to help businesses make better decisions, with a focus on expanding into new verticals and geographies. The company closed a $30 million Series C funding round in July 2015, led by Helion Venture Partners with $15 million from its fund, and participation from Desh Deshpande, Amar Sawhney, Rick Braddock, and Fred Khosravi. Sanjeev Aggarwal from Helion joined the board. At the time of the round, Axtria had approximately 400 employees and planned to grow headcount to 5,000-10,000, emphasizing sales and marketing hires for global expansion. New products were in development, including sales analytics for Salesforce.com and IoT applications in insurance and health. Prior to this raise, the company had achieved a revenue run rate of $30 million annually, building on earlier traction from pharmaceutical consulting projects that turned profitable in the first quarter after pivot. Axtria supported its growth through multiple prior rounds, including Series A in 2011 ($1.82M) and Series B in 2013 ($4.82M), with total funding reaching over $152 million across seven rounds by later years.
Jan 2014Series A-$5M-Axtria conducted a Series A funding round of $4.8 million on January 9, 2014. The company, founded in 2010, provides cloud software and data analytics to the life sciences industry.

Who has invested in Axtria?

7 investors have backed Axtria across its funding rounds, including Bain Capital, Helion Venture Partners, Kedaara Capital, Sparta Group, Richard Braddock and Amarpreet Sawhney.

Lead investors include Kedaara Capital, Bain Capital and Helion Venture Partners.


Axtria Investors

Investors in Axtria by funding rounds participated
InvestorHQRoundsRoleFirst check
Sparta GroupUnited StatesUnited States1ParticipantJul 2015
Amarpreet SawhneyUnited StatesUnited States1ParticipantJul 2015
Helion Venture PartnersMauritiusPort Louis1LeadJul 2015
Bain CapitalUnited StatesBoston, MA1LeadMay 2021
Kedaara CapitalIndiaMumbai1LeadSep 2025

This data is available for Pro users. Sign up to see all 7 Axtria investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Axtria

Axtria has acquired 1 company to date.

Last acquisition by Axtria was on April 14th 2026. Axtria acquired Conexus Solutions for undisclosed valuation.


Latest Acquisitions by Axtria

Conexus Solutions
Description
Conexus Solutions is a Princeton, New Jersey-based provider of cloud-based SaaS solutions for sales and marketing in small and mid-size companies, including CRM implementation, marketing programs, system integrations, data management, reporting, analysis, and customer support.
HQ CountryUnited States
HQ City
New York City, NY
Deal Date14 Apr 2026
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Axtria acquisitions and their M&A valuation multiples.

Start Free Trial

Axtria Competitors

Axtria competitors include listed companies like Claritev and HealthStream, and private ones like Huma.AI, Overjet, Saviynt and AgentSync.

Public and private companies comparable to Axtria
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Huma.AIUnited StatesRaleigh, NCPrivate--$1B-
OverjetUnited StatesBoston, MAPrivate--$712M-
SaviyntUnited StatesLos Angeles, CAPrivate$300M-$700M2.3x
AgentSyncUnited StatesDenver, COPrivate$11M-$1.2B109.1x
ClaritevUnited StatesUnited StatesPublicly listed$965M$466M$538M5.2x
HealthStreamUnited StatesUnited StatesPublicly listed$304M$63M$892M2.6x

Axtria Public Comps

Axtria is still privately-owned, but its public comps include HealthStream, MedicalSystem Technology, Hangzhou Pinming Software, Rezolve AI, Sphere, Appier Group, iFLYHealth, B-Soft Co., Vitec Software and Deluxe.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
HealthStream$304M$63M2.8x2.6x13.2x11.2x
MedicalSystem Technology$45M$12M18.9x15.6x70.7x62.9x
Hangzhou Pinming Software$65M$8M12.5x11.9x100.2x-
Rezolve AI$47M($109M)23.3x4.0x(10.0x)(19.3x)
Sphere$70M$6M14.3x6.9x156.3x103.0x
Appier Group$281M$44M3.4x2.9x21.6x15.7x
iFLYHealth$136M($7M)7.7x6.2x(150.8x)(144172.5x)
B-Soft Co.$157M($37M)4.7x4.8x(20.0x)(20.0x)

This data is available for Pro users. Sign up to see all Axtria competitors and their valuation data.

Start Free Trial

Common questions about Axtria

When was Axtria founded?Axtria was founded in 2010.
Where is Axtria headquartered?Axtria is headquartered in Berkeley Heights, NJ, United States.
Is Axtria publicly listed?No, Axtria is a private, VC-backed company.
What is Axtria's valuation?Axtria was last valued at $900M in its undisclosed-stage round in May 2021.
How much funding has Axtria raised?Axtria has raised $202M across 5 funding rounds.
What was Axtria's last funding round?Axtria's last funding round was a $150M undisclosed-stage round in May 2021, led by Bain Capital.
Who are Axtria's investors?Axtria's investors include Sparta Group, Amarpreet Sawhney, Helion Venture Partners, Bain Capital, Kedaara Capital, Farhad Khosravi and Richard Braddock.
Which companies are comparable to Axtria?Companies comparable to Axtria include Huma.AI, Overjet, Saviynt, AgentSync, Claritev and HealthStream.
How many companies has Axtria acquired?Axtria has acquired 1 company, including Conexus Solutions.

See companies similar to Axtria

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial